Hyfe logo

Hyfe measures cough as an objective, continuous signal and trial endpoint so respiratory research can move beyond subjective reports and short cough recording windows.

Our validated, privacy-preserving, on-device detection quantifies cough frequency and patterns in real-world conditions with high participant adherence, producing data that is clinically interpretable and operationally practical at scale. Hyfe’s cough monitoring technology takes participant privacy extremely seriously and at no point conversations or audio can be listened to, there are no audio recordings stored, just timestamps of coughs processed in real time as the system passively monitors ambient sound levels.

This is increasingly essential as cough frequency has become an efficacy endpoint in FDA-reviewed chronic cough programs and regulatory expectations continue to sharpen around measurement validity, traceability, and interpretability.

Hyfe is built to deliver regulator-grade objective cough endpoints and trend insights (cough bouts, cough-free time, cough variability, among other) without adding burden for patients, sites, or study teams.

Continuous, objective cough endpoint

Hyfe turns cough into a continuous, quantitative endpoint, capturing real-world variability and enabling more sensitive detection of treatment effects than episodic assessments or self-report.

image

Privacy-preserving and patient-friendly by design

High-quality data without trade-offs. On-device processing avoids audio capture (no one listens to participant conversations) and reduces privacy risk, while passive monitoring supports strong adherence.

image

Regulator-grade measurement with a clear acceptance pathway

Built for where regulation is heading. Objective cough frequency is already being used as an efficacy endpoint in FDA-reviewed programs, and the expectations are clear: validated methods, traceability, and clinical interpretability. Hyfe is designed to meet these expectations.

image

2025

October 16

DTx proof-of-concept results presented at CHEST 2025 in Chicago: 41.8% reduction in cough frequency and 80% of participants reporting clinically meaningful improvement in quality of life.

July

Multiple abstracts presented at ATS 2025 covering optimal monitoring duration, cough bout metrics, and the DTx proof-of-concept.

May

Six-month TB treatment monitoring study from Madagascar published in ERJ Open Research, showing cough rates dropping from 11.0 to 3.5 coughs/hour during treatment.

April

Scoping review in The Lancet Digital Health independently validates Hyfe as one of the leading non-contact autonomous cough detection systems.

February 24

Announces strategic partnership with KYORIN Pharmaceutical to develop and commercialize the world's first prescription digital therapeutic for chronic cough in Japan, with milestone payments and royalties.

January 28

Formal product launch of the ActiGraph-Hyfe combined digital health solution on ActiGraph's LEAP wearable platform.

January 6

Publishes multicenter clinical validation in Nature Scientific Reports showing 90.4% sensitivity, 1.03 false positives per hour, and 0.99 Pearson correlation with manual counts across 546 hours and 4,454 cough events.

2024

November

733,756-cough TB dataset from 2,143 patients across 7 countries published in Nature Scientific Data.

October

Collaboration with Sensory Cloud Inc. published in ERJ Open Research showing an inhaled alkaline salt aerosol reduced cough frequency by up to 35% in refractory chronic cough patients, monitored using the Hyfe CoughMonitor Suite.

2023

January

COVID-19 prognostication study published in Journal of Biomedical Informatics showing higher early cough rates predicted more favorable outcomes

December

Tamsin Chislett transitions into the CEO role, reflecting the company's shift from founder-led R&D to commercial scaling.

November–December

Landmark validation study published in BMJ Open Respiratory Research showing Hyfe's AI is nearly as accurate as the human ear in detecting coughs, including the first-ever observation of sex differences in cough characteristics.

August 17

Partners with ActiGraph to integrate cough detection into ActiGraph's FDA-cleared LEAP wearable for clinical research.

May

Dr. George Savage (co-founder of Proteus Digital Health) and Dr. Laurie Slovarp (world's leading BCST clinician) join the Scientific Advisory Board.

May 20

Announces plans to launch the world's first digital therapeutic (DTx) for chronic cough, incorporating Behavioral Cough Suppression Therapy (BCST).

2022

November

Named to the CB Insights Digital Health 150 list, selected from 13,000 private companies as one of the most promising digital health companies globally.

October

Multiple publications in ERJ Open Research and Lung demonstrate continuous longitudinal cough monitoring reveals patterns invisible to short-term assessments.

September

Presents at the European Respiratory Society (ERS) Congress in Barcelona.

July 19

Announces partnership with Merck to integrate Hyfe's AI cough tracker into Merck's consumer disease education efforts targeting an estimated 12 million U.S. adults with chronic cough.

May

Presents at the ATS 2022 Respiratory Innovation Summit with poster "Hyfe Cough Monitoring System: Making Cough Count."

March

Dr. Peter Small addresses the G20 meeting in Yogyakarta, Indonesia on digital innovation in combating tuberculosis.

2021

January

Featured in the Wall Street Journal ("Coughs Say a Lot About Your Health, If Your Smartphone Is Listening").

December

Hyfe's app incorporated into a year-long respiratory research trial with the University of Navarra, Zizur's Health Center, and Montreal University Hospital Center.

August–September

Dr. Peter Small appointed Chief Medical Officer, bringing credentials from Stanford Medical School, the Bill & Melinda Gates Foundation (where he developed the TB strategy), and as Founding Director of the Global Health Institute at Stony Brook University.

July

First major protocol paper published in BMJ Open, describing the digital acoustic surveillance study design deployed in Pamplona, Spain.

June

Partners with ObvioHealth to integrate cough tracking into their decentralized clinical trials platform — Hyfe's first clinical trials partnership.

May

Joins the Creative Destruction Lab and Health Engine Accelerator programs.

April

Closes ~$1M seed round led by a private investor with participation from Plug and Play Ventures.

February

Hyfe joins the Plug and Play accelerator program.

2020

November

Core AI technology development begins: a machine-learning engine that detects, classifies, and counts coughs from ambient sound on any device with a microphone, processing entirely on-device to preserve privacy.

July

Reid Moorsmith joins as Director of Consumer Products, bringing global health operations experience from PSI programs in Liberia and Myanmar.

May

Hyfe founded by Joe Brew (epidemiologist/data scientist), Iulian Circo (serial entrepreneur), and Paul Rieger (software developer) in Wilmington, Delaware.